October 19, 2020

MedRxiv Pre-print

Today, the Consortium of Independent Immunology Clinics (CIIC) announced a recent pre-print in MedRxiv, co-authored by its member, Dr. Oral Alpan.

Link to Dr. Alpan’s MedRxiv pre-print.

Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19

• Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development.
  • Research team developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays.
  • SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n=115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected.
  • SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs).
  • Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors.
  • Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus.
  • Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.

Dr. Oral Alpan is an Allergist and Clinical Immunologist and the Director of Immunopathogenesis section at O & O Alpan, LLC.  Dr. Alpan is the founder of Amerimmune, the only commercial Clinical Consultative Flow Cytometry program that provides clinical laboratory immunology services. Dr. Alpan is also the co-director of Eosinophilic Gastrointestinal Disorders unit. He has been a principal investigator in Phase II, III, IIIb and IV studies, and authored many publications in basic and clinical immunology and allergy. He has been a member of the CIIC since its inception.

The CIIC is a professional medical organization formed in 2013 and comprised of select Board Certified Immunologists in private practice throughout the USA. We provide high quality care for patients with Primary Immune Deficiency Disorders (PIDD), promote access to treatment, serve as advocates to patients and physicians who care for PIDD patients and participate in research that benefits patient care.

CIIC Mission – Provide cutting edge therapy to patients with Primary Immune Deficiency

View Press Release